Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

MLA

Linyan Cheng, et al. “Efficacy and Safety of Bispecific Antibodies vs. Immune Checkpoint Blockade Combination Therapy in Cancer: A Real-World Comparison.” Molecular Cancer, vol. 23, no. 1, Apr. 2024, pp. 1–39. EBSCOhost, https://doi.org/10.1186/s12943-024-01956-6.

APA

Linyan Cheng, Lujun Chen, Yuan Shi, Weiying Gu, Weidong Ding, Xiao Zheng, Yan Liu, Jingting Jiang, & Zhuojun Zheng. (2024). Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison. Molecular Cancer, 23(1), 1–39. https://doi.org/10.1186/s12943-024-01956-6

Chicago

Linyan Cheng, Lujun Chen, Yuan Shi, Weiying Gu, Weidong Ding, Xiao Zheng, Yan Liu, Jingting Jiang, and Zhuojun Zheng. 2024. “Efficacy and Safety of Bispecific Antibodies vs. Immune Checkpoint Blockade Combination Therapy in Cancer: A Real-World Comparison.” Molecular Cancer 23 (1): 1–39. doi:10.1186/s12943-024-01956-6.